精品国产亚洲国产亚洲,久热中文在线观看精品视频,成人三级av黄色按摩,亚洲AV无码乱码国产麻豆

The labelled natural cytokinins can be distinguished in the MS analysis because the m/z values of their mass spectral fragments are displaced by several mass units (m/z > 2 amu). A known quantity of the labelled cytokinin is added to the initial extract, and after purification the molar ratio of natural cytokinin to labelled internal standard is determined by mass spectrometry. The quantitative analysis by MS was first carried out by Thompson et al., Planta, 124: 207, 1975.

[¹⁵N₅]ADENINE (¹⁵N-Ade) [6-amino[¹⁵N₅]purine]

MW 139.10; crystalline; purity > 97% (HPLC)
R:22, S:22, 36; C5H515N5
	030 0241	1	mg
	030 0242	2	mg
	030 0243	5	mg

[²H₇]N⁶-BENZYLADENINE (D-BA) [6-[²H₇]benzylaminopurine]

MW 232.29; crystalline; purity > 97% (HPLC)
R:36/37/38, S:26, 36; CAS: 147028-87-3; C12H42H7N5
	030 0221	1	mg
	030 0222	2	mg
	030 0223	5	mg

[²H₇]N⁶-BENZYLADENOSINE (D-BAR) [6-[²H₇]benzylamino-9-β-D-ribofuranosylpurine]

MW 364.41; crystalline; purity > 97% (HPLC)
S:26, 36; C17H122H7N5O4
	030 0551	1	mg
	030 0552	2	mg
	030 0553	5	mg

[²H₇]N⁶-BENZYLADENINE-9-GLUCOSIDE (D-BA9G) [6-[²H₇]benzylamino-9-β-D-glucopyranosylpurine]

MW 394.44; crystalline; purity > 97% (HPLC)
R: 36/37/38, S: 26, 36; C18H142H7N5O5
	030 3281	1	mg
	030 3282	2	mg
	030 3283	5	mg

[²H₇]N⁶ - BENZYLADENOSINE-5'-MONOPHOSPHATE SODIUM SALT (D-BAMP) [6-[²H₇]benzylamino-9-β-D-ribofuranosylpurine-5'-monophosphate disodium monohydrate]

MW 506.38; crystalline; purity > 95% (HPLC)
S:26, 36; C17H112H7N5Na2O7P.H2O
	030 5001	1	mg
	030 5002	2	mg
	030 5003	5	mg

[²H₃]DIHYDROZEATIN (D-DHZ) [6-[²H₃](4-hydroxy-3-methylbutylamino)purine]

MW 224.28; crystalline; purity > 98% (HPLC)
S:26, 36; CAS: 175733-30-9; C10H122H3N5O
	030 0601	1	mg
	030 0602	2	mg
	030 0603	5	mg

[¹⁵N-N⁴]DIHYDROZEATIN (15N-DHZ) [6-[¹⁵N-N⁴](4-hydroxy-3-methylbutylamino)purine]

MW 225.24; crystalline; purity > 98% (HPLC)
S:26, 36; C10H12N15N4O
	030 7021	1	mg
	030 7022	2	mg
	030 7023	5	mg

[²H₃]DIHYDROZEATIN RIBOSIDE (D-DHZR)[6-[²H₃](4-hydroxy-3-methylbutylamino)-9-β-D-ribofuranosylpurine]

MW 356.40; crystalline; purity > 97% (HPLC)
S:26, 36; CAS: 175733-31-0; C15H202H3N5O5
	030 0611	1	mg
	030 0612	2	mg
	030 0613	5	mg

[²H₃]DIHYDROZEATIN RIBOSIDE-5'-MONOPHOSPHATE (D-DHZMP) [6-[²H₃](4-hydroxy-3-methylbutylamino)-9-β-D-ribofuranosyl purine-5'-monophosphate disodium monohydrate]

MW 498.36; crystalline; purity > 95% (HPLC)
S:26, 36; C15H192H3N5Na2O8P.H2O
	030 5011	1	mg
	030 5012	2	mg
	030 5013	5	mg

[²H₃]DIHYDROZEATIN-9-GLUCOSIDE (D-DHZ9G)[6-[²H₃](4-hydroxy-3-methylbutylamino)-9-β-D-glucopyranosylpurine]

MW 386.43; crystalline; purity > 95% (HPLC)
S:26, 36; C16H222H3N5O6
	030 0631	1	mg
	030 0632	2	mg
	030 0633	5	mg

[²H₇]DIHYDROZEATIN-O-GLUCOSIDE (D-DHZOG) [6-[²H₇](4-hydroxy-3-methylbytylamino)-O-β-D-glucopyranosylpurine]

MW 390.45; crystalline; purity > 95% (HPLC)
S:26, 36; C16H182H7N5O6
	030 0641	1	mg
	030 0642	2	mg
	030 0643	5	mg

[²H₇]DIHYDROZEATIN-O-GLUCOSIDE RIBOSIDE (D-DZROG) [6-[²H₇](4-hydroxy-3-methylbutylamino)-9-β-D-ribofuranosyl-O-β-D-glucopyranosylpurine]

MW 522.56; crystalline; purity > 95% (HPLC)
S:26, 36; C21H262H7N5O10
	030 0651	1	mg
	030 0652	2	mg
	030 0653	5	mg

[¹⁵N-N⁴]HYPOXANTINE (15N-Hyp) [6-[¹⁵N-N⁴]hydroxypurine]

MW 140.09; crystalline; purity > 97% (HPLC)
S:26, 36; C5H415N4O
	030 5941	1	mg
	030 5942	2	mg
	030 5943	5	mg

[²H₆]N⁶-ISOPENTENYLADENINE (D-iP) [6-[²H₆](3,3-dimethylallylamino)purine]

MW 209.29; crystalline; purity > 98% (HPLC)
S:26, 36; CAS: 175733-28-5; C10H72H6N5
	030 0161	1	mg
	030 0162	2	mg
	030 0163	5	mg

[¹⁵N₄-N⁶]-ISOPENTENYLADENINE (15N4-iP) [6-[¹⁵N₄](3,3-dimethylallylamino)purine]

MW 207.22; crystalline; purity > 98% (HPLC)
S:26, 36; C10H1315N4N
	030 7371	1	mg
	030 7372	2	mg
	030 7373	5	mg

[²H₆]N⁶-ISOPENTENYLADENOSINE (D-iPR) [6-[²H₆](3,3-dimethylallylamino)-9-β-D-ribofuranosylpurine]

MW 341.41; crystalline; purity > 98% (HPLC)
S:26, 36; CAS: 175733-29-6; C15H152H6N5O4
	030 0171	1	mg
	030 0172	2	mg
	030 0173	5	mg

[¹⁵N]N⁶-ISOPENTENYLADENOSINE (15N-iPR) [6-[¹⁵N](3,3-dimethylallylamino)-9-β-D-ribofuranosylpurine]

MW 336.36; crystalline; purity > 98% (HPLC)
S:26, 36; C15H21N415NO4
	030 7031	1	mg
	030 7032	2	mg
	030 7033	5	mg

[²H₆]N⁶-ISOPENTENYLADENOSINE-5'-MONOPHOSPHATE (D-iPMP) [6[²H₆]-(3,3-dimethylallylamino)-9-β-D-ribofuranosylpurine-5'-monophosphate disodium monohydrate]

MW 483.37; crystalline; purity > 95% (HPLC)
S:26, 36; C15H142H6N5Na2O7P.H2O
	030 5041	1	mg
	030 5042	2	mg
	030 5043	5	mg

[²H₆]N⁶-ISOPENTENYLADENINE-7-GLUCOSIDE(D-iP7G)[6-[²H₆] (3,3-dimethylallylamino)-7-β-D-glucopyranosylpurine]

MW 371.43; crystalline; purity > 95% (HPLC)
S:26, 36; C16H172H6N5O5
	030 5051	1	mg
	030 5052	2	mg
	030 5053	5	mg

[²H6] N⁶-ISOPENTENYLADENINE-9-GLUCOSIDE (D-iP9G) [6-[²H₆] (3,3-dimethylallylamino)-9-β-D-glucopyranosylpurine]

MW 371.43; crystalline; purity > 95% (HPLC)
S:26, 36; C16H172H6N5O5
	030 0231	1	mg
	030 0232	2	mg
	030 0233	5	mg

[²H₆]2-METHYLTHIO-N⁶-ISOPENTENYLADENINE (D-2MeSiP) [2-methylthio-6-[²H₆](3,3-dimethylallylamin)purine]

MW 255.38; crystalline; purity > 95% (HPLC)
S:26, 36; C10H72H6N5S
	030 5071	1	mg
	030 5072	2	mg
	030 5073	5	mg

[²H₆]2-METHYLTHIO-N⁶-ISOPENTENYLADENOSINE (D-2MeSiPR) [2-methylthio-6-[²H₆](3,3-dimethylallylamino)-9-β-D-ribofuranosylpurine]

MW 387.50; crystalline; purity > 95% (HPLC)
S:26, 36; C16H172H6N5O4S
	030 5061	1	mg
	030 5062	2	mg
	030 5063	5	mg

[¹⁵N₄]KINETIN(15N-K) [6-furfurylamino[¹⁵N₄]purine]

MW 219.19; CRYSTALLINE; purity > 97% (HPLC)
S:26, 36; C10H9N15N4O
	030 0341	1	mg
	030 0342	2	mg
	030 0343	5	mg

[¹⁵N-N⁴]meta-METHOXYTOPOLIN (15N-MemT) [6-(3-methoxybenzylamino)[¹⁵N₄]purine]

MW 259.25; crystalline; purity > 98% (HPLC)
S:26, 36; C13H13N15N4O
	030 0511	1	mg
	030 0512	2	mg
	030 0513	5	mg

[¹⁵N₄]meta-TOPOLIN (15N-mT) [6-(3-hydroxybenzylamino)[¹⁵N₄]purine]

MW 245.23; CRYSTALLINE; purity >97% (HPLC)
S:26, 36; C12H11N15N4O
	030 0101	1	mg
	030 0102	2	mg
	030 0103	5	mg

[¹⁵N₄]ortho-TOPOLIN (15N-oT) [6-(2-hydroxybenzylamino)[¹⁵N₄]purine]

MW 245.23; CRYSTALLINE; purity >98% (HPLC)
S:26, 36; C12H11N15N4O
	030 0121	1	mg
	030 0122	2	mg
	030 0123	5	mg

[¹⁵N₄]para-TOPOLIN (15N-pT) [6-(4-hydroxybenzylamino)[¹⁵N₄]purine]

MW 245.23; CRYSTALLINE; purity >98% (HPLC)
S:26, 36; C12H11N15N4O
	030 0451	1	mg
	030 0452	2	mg
	030 0453	5	mg

[²H₅]trans-ZEATIN (D-tZ)[6-[²H₅]((E)-4-hydroxy-3-methylbut-2-enylamino)purine]

MW 224.28; crystalline; purity > 98% (HPLC); cis isomer <5%
S:26, 36; CAS: 72963-19-0; C10H82H5N5O
	030 0301	1	mg
	030 0302	2	mg
	030 0303	5	mg

[¹⁵N]trans-ZEATIN (15N-tZ) [6-((E)-4-hydroxy-3-methylbut-2-enylamino) purine]

MW 220.24; crystalline; purity > 98% (HPLC)
S:26, 36; C10H13N415NO
	030 7041	1	mg
	030 7042	2	mg
	030 7043	5	mg

[¹⁵N₄]trans-ZEATIN (15N4-tZ) [6-[¹⁵N₄]((E)-4-hydroxy-3-methylbut-2-enylamino) purine]

MW 223.22; crystalline; purity > 98% (HPLC)
S:26, 36; C10H1315N4NO
	030 7381	1	mg
	030 7382	2	mg
	030 7383	5	mg

[²H₅]trans-ZEATIN RIBOSIDE (D-tZR) [6-[²H₅]((E)-4-hydroxy-3-methylbut-2-enylamino)-9-β-D-ribofuranosylpurine]

MW 356.40; crystalline; purity > 97% (HPLC); cis isomer <0.2%
S:26, 36; CAS: 72963-21-4; C15H162H5N5O5
	030 0311	1	mg
	030 0312	2	mg
	030 0313	5	mg

[²H₅]trans-ZEATIN-7-GLUCOSIDE (D-tZ7G) [6-[²H₅]((E)-4-hydroxy-3-methylbut-2-enylamino)-7-β-D-glucopyranosylpurine]

MW 386.42; crystalline; purity > 95% (HPLC)
S:26, 36; C16H182H5N5O6
	030 5111	1	mg
	030 5112	2	mg
	030 5113	5	mg

[²H₅]trans-ZEATIN-9-GLUCOSIDE (D-tZ9G) [6-[²H₅]((E)-4-hydroxy-3-methylbut-2-enylamino)-9-β-D-glucopyranosylpurine]

MW 386.42; crystalline; purity > 95% (HPLC)
S:26, 36; CAS: 84744-92-3; C16H182H5N5O6
	030 0471	1	mg
	030 0472	2	mg
	030 0473	5	mg

[²H₅]trans-ZEATIN-O-GLUCOSIDE (D-tZOG) [6-[²H₅]((E)-4-hydroxy-3-methylbut-2-enylamino)-O-β-D-glucopyranosylpurine]

MW 386.42; crystalline; purity > 95% (HPLC)
S:26, 36; CAS: 72963-23-6; C16H182H5N5O6
	030 5121	1	mg
	030 5122	2	mg
	030 5123	5	mg

[²H₅]trans-ZEATIN-O-GLUCOSIDE RIBOSIDE (D-tZROG) [6-[²H₅]((E)-4-hydroxy-3-methylbut-2-enylamino)-9-β-D-ribofuranosyl-O-β-D-glucopyranosylpurine]

MW 518.54; crystalline; purity > 95% (HPLC)
S:26, 36; CAS: 69700-29-4; C21H262H5N5O10
	030 5131	1	mg
	030 5132	2	mg
	030 5133	5	mg

[²H₅]trans-ZEATIN RIBOSIDE-5'-MONOPHOSPHATE (D-tZMP) [6-[²H₅]((E)-4-hydroxy-3-methylbut-2-enylamino)-9-β-D-ribofuranosylpurine-5'-monophosphate disodium monohydrate]

MW 498.29; crystalline; purity > 95% (HPLC)
S:26, 36; C15H152H5N5Na2O8P.H2O
	030 5141	1	mg
	030 5142	2	mg
	030 5143	5	mg

[²H₅]2-METHYLTHIO-trans-ZEATIN (D-2MetSZ) [2-methylthio-6-[²H₅]((E)-4-hydroxy-3-methylbut-2-enylamino)purine]

MW 270.37; crystalline; purity > 95% (HPLC)
S:26, 36; C11H102H5N5OS
	030 5171	1	mg
	030 5172	2	mg
	030 5173	5	mg

[²H₅]2-METHYLTHIO-trans-ZEATIN RIBOSIDE (D-2MeStZR) [2-methylthio-6-[²H₅]((E)-4-hydroxy-3-methylbut-2-enylamino)-9-β-D-ribofuranosylpurine]

MW 402.49; crystalline; purity > 95% (HPLC)
S:26, 36; C16H182H5N5O5S
	030 5181	1	mg
	030 5182	2	mg
	030 5183	5	mg

[¹⁵N₄]cis-ZEATIN (15N-cZ) [6-[¹⁵N₄]((Z)-4-hydroxy-3-methylbut-2-enylamino) purine]

MW 223.22; crystalline; purity > 98% (HPLC)
S:26, 36; C10H13N15N4O
	030 0321	1	mg
	030 0322	2	mg
	030 0323	5	mg